Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations

Alexander Janssen, Frank C. Bennis, Marjon H. Cnossen, Ron A. A. Mathôt, for the OPTI-CLOT study group SYMPHONY consortium, S. H. Reitsma, F. W. G. Leebeek, M. Coppens, K. Fijnvandraat, K. Meijer, S. E. M. Schols, H. C. J. Eikenboom, R. E. G. Schutgens, F. Heubel-Moenen, L. Nieuwenhuizen, P. Ypma, M. H. E. Driessens, I. van Vliet, M. J. H. A. Kruip, S. PolinderP. Brons, F. J. M. van der Meer, K. Fischer, K. van Galen, P. W. Collins, M. Mathias, P. Chowdary, D. Keeling, J. Lock, H. C. A. M. Hazendonk, T. Preijers, N. C. B. de Jager, L. Schutte, L. H. Bukkems, M. C. H. J. Goedhart, J. M. Heijdra, L. Romano, W. Al Arashi, M. E. Cloesmeijer, S. F. Koopman, C. Mussert

Research output: Contribution to JournalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)797-808
JournalJournal of Pharmacokinetics and Pharmacodynamics
Volume51
Issue number6
DOIs
Publication statusPublished - Dec 2024

Funding

SYMPHONY consortium: The SYMPHONY consortium which aims to orchestrate personalized treatment in patients with bleeding disorders, is a unique collaboration between patients, health care professionals, and translational and fundamental researchers specialized in inherited bleeding disorders, as well as experts from multiple disciplines. It aims to identify best treatment choice for each individual based on bleeding phenotype. To achieve this goal, workpackages have been organized according to 3 themes e.g. Diagnostics (workpackages 3 and 4); Treatment (workpackages 5-9) and Fundamental Research (workpackages 10\u201312). This research receives funding from the Netherlands Organisation for Scientific Research (NWO) in the framework of the NWA-ORC Call grant agreement NWA.1160.18.038. Principal investigator: Dr. M.H. Cnossen. Project coordinator: Dr. S.H. Reitsma. Beneficiaries of the SYMPHONY consortium: Erasmus University Medical Center-Sophia Children\u2019s Hospital, project leadership and coordination; Sanquin Diagnostics; Sanquin Research; Amsterdam University Medical Centers; University Medical Center Groningen; University Medical Center Utrecht; Leiden University Medical Center; Radboud University Medical Center; Netherlands Society of Hemophilia Patients (NVHP); Netherlands Society for Thrombosis and Hemostasis (NVTH); Bayer B.V., CSL Behring B.V., Swedish Orphan Biovitrum (Belgium) BVBA/SPRL.\u200B Additional beneficiaries, not included in the SYMPHONY consortium, currently funding parallel projects are: Novonordisk (OPTI-CLOT TARGET), Roche (Partitura), Stichting Haemophilia (patient-reported outcomes project). OPTI-CLOT study group: OPTI-CLOT/To WiN study group aims to implement personalized treatment by pharmacometric-guided dosing of factor concentrates, desmopressin and nonfactor therapies in patients with bleeding disorders. OPTI-CLOT/To WiN Steering Committee, the Netherlands: M.H. Cnossen (principal Investigator &; chair OPTI-CLOT-To WiN) and R.A.A. Math\u00F4t (coinvestigator). F.W.G. Leebeek, Rotterdam;, M. Coppens K. Fijnvandraat, Amsterdam; K. Meijer, Groningen, S.E.M. Schols, Nijmegen; H.C.J. Eikenboom, Leiden; R.E.G. Schutgens, Utrecht; F. Heubel-Moenen, Maastricht; L. Nieuwenhuizen, Veldhoven; P. Ypma, The Hague; M.H.E. Driessens, Nijkerk. Trial bureau: I. van Vliet, Rotterdam. Local collaborators the Netherlands: M.J.H.A. Kruip, S. Polinder, Rotterdam; P. Brons,Nijmegen; F.J.M. van der Meer, Leiden; K. Fischer, K. van Galen, Utrecht. Principal investigators and local collaborators in the UK: P. W. Collins, Cardiff; M. Mathias, P. Chowdary, London; D. Keeling, Oxford. OPTI-CLOT-To WiN, DAVID and SYMPHONY PhDs: PhDs: J. Lock, H.C.A.M. Hazendonk, T. Preijers, N.C.B. de Jager, L. Schutte, L.H. Bukkems. PhDs ongoing: M.C.H.J. Goedhart, J.M. Heijdra, L. Romano, W. Al Arashi, M.E. Cloesmeijer, A. Janssen, S.F. Koopman, C. Mussert. SYMPHONY consortium: The SYMPHONY consortium which aims to orchestrate personalized treatment in patients with bleeding disorders, is a unique collaboration between patients, health care professionals, and translational and fundamental researchers specialized in inherited bleeding disorders, as well as experts from multiple disciplines. It aims to identify best treatment choice for each individual based on bleeding phenotype. To achieve this goal, workpackages have been organized according to 3 themes e.g. Diagnostics (workpackages 3 and 4); Treatment (workpackages 5-9) and Fundamental Research (workpackages 10\u201312). This research receives funding from the Netherlands Organisation for Scientific Research (NWO) in the framework of the NWA-ORC Call grant agreement NWA.1160.18.038. Principal investigator: Dr. M.H. Cnossen. Project coordinator: Dr. S.H. Reitsma.

FundersFunder number
Erasmus University Medical Center-Sophia Children’s Hospital
Leids Universitair Medisch Centrum
Netherlands Society for Thrombosis and Hemostasis
Netherlands Society of Hemophilia Patients
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Bayer B.V.
Nederlandse Vereniging voor Trombose en Hemostase
Radboud Universitair Medisch Centrum
NVHP
Roche
Stichting Haemophilia
University Medical Center Utrecht
CSL Behring B.V.
Fundamental Research10–12
NWA-ORCNWA.1160.18.038

    Cite this